Aditxt, Inc. (ADTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2711 |
| Open | 0.2600 |
| Bid | 0.2779 x 1100 |
| Ask | 0.2950 x 3000 |
| Day's Range | 0.2600 - 0.2958 |
| 52 Week Range | 0.2410 - 3.9500 |
| Volume | |
| Avg. Volume | 603,112 |
| Market Cap | 12.97M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7200 |
| Earnings Date | Nov 13, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ADTX
Related Research
- Aditxt, Inc.Daily – Vickers Top Insider Picks for 05/26/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat3 days agoArgus Research
- Business Wire
Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth
RICHMOND, Va., April 14, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, today is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse Guthy-Renker, LLC ("Guthy-Renker"). This partnership will focus on building awareness and visibility among consumers and healthcare providers for the AditxtScore™ Immune Monitoring Platform. Aditxt plans to work
- Business Wire
Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th
RICHMOND, Va., April 05, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX) has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the Company’s $14.5 million loan, plus interest to Cellvera Global Holdings LLC ("Cellvera"), formerly AiPharma Global Holdings LLC. The Company has signed the agreement as consideration for Aditxt’s separa
- Business Wire
Aditxt to Participate in the 2022 Virtual Growth Conference
RICHMOND, Va., March 23, 2022--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced today that Company CEO & Co-Founder, Amro Albanna, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
